The evolving landscape of combination therapies in lung cancer

Immuno-Oncology Insights 2024; 5(2), 57–63

DOI: 10.18609/ioi.2024.009

Published: 25 March
Heather Wakelee

Lauren Coyle, Commissioning Editor of Immuno-Oncology Insights, speaks with Heather Wakelee, Chief of the Division of Oncology at Stanford University, about the advancements on lung cancer treatment with targeted therapies and immunotherapy combinations. Their conversation also covers notable clinical trials with CTLA-4, TIGIT, and ADCs and the best strategies to optimize personalized medicine.